活性氧
药理学
氧化应激
SOD2
线粒体
体内
蛋白激酶B
PI3K/AKT/mTOR通路
化学
氧化磷酸化
粒体自噬
心肌保护
抗氧化剂
细胞凋亡
生物化学
医学
超氧化物歧化酶
生物
缺血
自噬
内科学
生物技术
作者
Yu Sun,Pu Zhang,Yuqing Li,Ya‐Jun Hou,Chenyang Yin,Zekun Wang,Ziyu Liao,Xiaoyan Fu,Man Li,Cundong Fan,Dongdong Sun,Liang Cheng
出处
期刊:ACS Nano
[American Chemical Society]
日期:2022-10-20
卷期号:16 (11): 18667-18681
被引量:41
标识
DOI:10.1021/acsnano.2c07311
摘要
Mitochondrial dysfunction and oxidative damage represent important pathological mechanisms of myocardial ischemia-reperfusion injury (MI/RI). Searching for potential antioxidant agents to attenuate MI/RI is of great significance in clinic. Herein, gold–selenium core–shell nanostructures (AS-I/S NCs) with good near-infrared (NIR)-II photoacoustic imaging were designed for MI/RI treatment. The AS-I/S NCs after ischemic myocardium-targeted peptide (IMTP) and mitochondrial-targeted antioxidant peptide SS31 modification achieved cardiomyocytes-targeted cellular uptake and enhanced antioxidant ability and significantly inhibited oxygen-glucose deprivation-recovery (OGD/R)-induced cardiotoxicity of H9c2 cells by inhibiting the depletion of mitochondrial membrane potential (MMP) and restoring ATP synthase activity. Furthermore, the AS-I/S NCs after SS31 modification achieved mitochondria-targeted inhibition of reactive oxygen species (ROS) and subsequently attenuated oxidative damage in OGD/R-treated H9c2 cells by inhibition of apoptosis and oxidative damage, regulation of MAPKs and PI3K/AKT pathways. The in vivo AS-I/S NCs administration dramatically improved myocardial functions and angiogenesis and inhibited myocardial fibrosis through inhibiting myocardial apoptosis and oxidative damage in MI/RI of rats. Importantly, the AS-I/S NCs showed good safety and biocompatibility in vivo. Therefore, our findings validated the rational design that mitochondria-targeted selenium–gold nanocomposites could attenuate MI/RI of rats by inhibiting ROS-mediated oxidative damage and regulating MAPKs and PI3K/AKT pathways, which could be a potential therapy for the MI/RI treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI